Skip to main content
Journal cover image

Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane.

Publication ,  Conference
Miller, KD; Rugo, HS; Cobleigh, MA; Marcom, PK; Chap, LI; Holmes, FA; Fehrenbacher, L; Overmoyer, BA; Reimann, JD; Vassel, AV; Langmuir, VK
Published in: BREAST CANCER RESEARCH AND TREATMENT
December 1, 2002

Duke Scholars

Published In

BREAST CANCER RESEARCH AND TREATMENT

ISSN

0167-6806

Publication Date

December 1, 2002

Volume

76

Start / End Page

S37 / S37

Location

SAN ANTONIO, TEXAS

Publisher

KLUWER ACADEMIC PUBL

Conference Name

25th San Antonio Breast Cancer Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Miller, K. D., Rugo, H. S., Cobleigh, M. A., Marcom, P. K., Chap, L. I., Holmes, F. A., … Langmuir, V. K. (2002). Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. In BREAST CANCER RESEARCH AND TREATMENT (Vol. 76, pp. S37–S37). SAN ANTONIO, TEXAS: KLUWER ACADEMIC PUBL.
Miller, K. D., H. S. Rugo, M. A. Cobleigh, P. K. Marcom, L. I. Chap, F. A. Holmes, L. Fehrenbacher, et al. “Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane.” In BREAST CANCER RESEARCH AND TREATMENT, 76:S37–S37. KLUWER ACADEMIC PUBL, 2002.
Miller KD, Rugo HS, Cobleigh MA, Marcom PK, Chap LI, Holmes FA, et al. Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. In: BREAST CANCER RESEARCH AND TREATMENT. KLUWER ACADEMIC PUBL; 2002. p. S37–S37.
Miller KD, Rugo HS, Cobleigh MA, Marcom PK, Chap LI, Holmes FA, Fehrenbacher L, Overmoyer BA, Reimann JD, Vassel AV, Langmuir VK. Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. BREAST CANCER RESEARCH AND TREATMENT. KLUWER ACADEMIC PUBL; 2002. p. S37–S37.
Journal cover image

Published In

BREAST CANCER RESEARCH AND TREATMENT

ISSN

0167-6806

Publication Date

December 1, 2002

Volume

76

Start / End Page

S37 / S37

Location

SAN ANTONIO, TEXAS

Publisher

KLUWER ACADEMIC PUBL

Conference Name

25th San Antonio Breast Cancer Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences